Despite being recognized as a distinct clinical entity nearly 70 years ago, allergic
bronchopulmonary aspergillosis/mycosis (ABPA), which is what we would today—with our
vastly greater understanding of pathobiology—term an asthma endotype, 1 remains a
difficult and often long-delayed diagnosis. It is notable that in the 1952 landmark study by
Hinson et al, 2 the essential components of diagnosis were ''recurrent pyrexial attacks,
radiological evidence of recurrent collapse and consolidation in different areas, purulent …